medigraphic.com
ISSN 1561-302X (Print)

2023, Number 1

<< Back Next >>

Rev cubana med 2023; 62 (1)

Pro-BNP Peptide as a Predictor of Cardiac Damage in Systemic Sclerosis Patients

Chico CA, Estévez TMH, Castro AÁM, Gálvez VJF, Puente CRD

Language: Spanish
References: 24
Page: 1-11
PDF size: 372.63 Kb.


ABSTRACT

Introduction: Systemic sclerosis is a chronic autoimmune connective tissue disease of unknown cause, which produces excess collagen causing fibrosis in the skin, affecting internal organs. Common antibodies are antitopoisomerase 1 and anticentromere. The clinical forms are diffuse cutaneous and limited cutaneous. The prevalence of cardiac involvement varies between 8-28% and in late stages the presence of cardiovascular signs and symptoms have poor prognosis and one of the main causes of mortality.
Objective: To determine the association between cardiac involvement and clinical forms, N-terminal pro-brain natriuretic peptide (NT-proBNP) and autoantibodies in SSc.
Methods: A cross-sectional descriptive study of a universe of 140 patients was carried out. Fifty four patients made up the sample. An echocardiogram, NT-proBNP, Anti-scl 70, anticentromere levels and determination of clinical forms were performed on all patients who met the inclusion criteria and who were treated at Hermanos Ameijeiras hospital in Havana, Cuba, from July 2016 to December 2017.
Results: The mean age was 51.76 ± 12.82. Female sex accounted 96.3%. 72.2% were white skinned. Cardiac involvement of EScd was 77.5%, NT-proBNP hormone had high levels in 55.0%. Anti-scl-70 were negative in 70% (n=28) of patients with cardiac involvement. Anti-centromere (ACT) was negative in 95.0% (n=38).
Conclusions: Cardiac involvement in patients with SS is independent of the clinical forms and the presence of autoantibodies. Patients with elevated NT-proBNP serum levels had cardiac involvement.


REFERENCES

  1. Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304-20. DOI: http://doi.org/10.1016/S2213-2600(19)30480-11.

  2. Coffey CM, Radwan YA, Sandhu AS, Crowson CS, Bauer PR, Matteson EL, et al. Epidemiology and Trends in Survival of Systemic Sclerosis in Olmsted County (1980-2018): A Population-based Study. J Scleroderma Relat Disord. 2021;6(3):264-70. DOI: http://doi.org/10.1177/239719832110268532.

  3. Bairkdar M, Rossides M, Westerlind H, Hesselstrand R, Arkema EV, Holmqvist M. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(7):3121-33. DOI: http://doi.org/10.1093/rheumatology/keab1903.

  4. Kawano H, Kudo T, Umeda M, Futakuchi M, Sueyoshi E, Maemura K. Myocardial Damage and Microvasculopathy in a Patient With Systemic Sclerosis. Circ J. 2021;85(2):224. DOi: http://doi.org/10.1253/circj.CJ-20-11334.

  5. Hosberg MC, Davidica Mayes M, Assassi S. Conective Tissue disorders, Classification and Epidemiology of scleroderma. 6ta ed. v(1) 2015. p 1153-8.

  6. Diab S, Dostrovsky N, Hudson M, Tatibouet S, Fritzler MJ, Baron M. Canadian Scleroderma Research Group. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. J Rheumatol. 2014;41(11):2179-85. DOI: http://doi.org/10.3899/jrheum.1402366.

  7. Hassaan M L. Sociedad Argentina de Dermatología. Consenso sobre esclerodermia 2015. P. 1-30.

  8. Medina Yimy F, Ortiz M, Barrera N, Chalem P, Motta A, Zamora F, et al. Relación de los experimentos anti-péptido citrulinado con manifestaciones osteoarticulares en una cohorte de pacientes con esclerodermia. Rev. Colomb. Reumatol. 2011 [acceso 05/03/2022];18(3):155-62. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-81232011000300002&lng=en8.

  9. Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatology (Oxford). 2009;48 Suppl 3:iii45-8. DOI: http://doi.org/10.1093/rheumatology/kep1109.

  10. Bell Castillo J, George Carrión W, García Céspedes ME, Rodríguez López J, George Bell M. Esclerosis sistémica progresiva en una mujer joven. MEDISAN 2015 [acceso 05/03/2022];19(5):628-37. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192015000500008&lng=es10.

  11. Grosso O, Silver H. Insuficiencia cardíaca vol.(6)3, 2011 p 106-11.

  12. Foocharoen C, Pussadhamma B, Mahakkanukrauh A, Suwannaroj S, Nanagara R. Asymptomatic cardiac involvement in Thai systemic sclerosis: prevalence and clinical correlations with non-cardiac manifestations (preliminary report). Rheumatology (Oxford). 2015;54(9):1616-21. DOI: http://doi.org/10.1093/rheumatology/kev09612.

  13. Champion HC. The heart in scleroderma. Rheum Dis Clin North Am. 2008;34(1):181-90;viii. DOI: http://doi.org/10.1016/j.rdc.2007.12.00213.

  14. Oram S, Stokes W. The heart in scleroderma. Br Heart J. 1961;23(3):243-59. DOI: http://doi.org/10.1136/hrt.23.3.24314.

  15. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46(3):428-40. DOI: http://doi.org/10.1016/0002-9343(69)90044-815.

  16. González D. Respuesta clínica y ecocardiográfica en pacientes con hipertensión pulmonar y esclerosis sistémica tratados con sildenafil, Universidad central de Ecuador. 2015. p 1-85.

  17. Byers RJ, Marshall DAS, Freemont AJ, Pericardial involvement in systemic sclerosis. Annals of the Rheumatic Diseases 1997;56:393-4.

  18. Satoh M, Tokuhira M, Hama N, Hirakata M, Kuwana M, Akizuki M. Massive pericardial effusion in scleroderma: a review of five cases. Br J Rheumatol. 1995;34(6):564-7. DOI: http://doi.org/10.1093/rheumatology/34.6.56418.

  19. Meune C, Allanore Y, Devaux JY, Dessault O, Duboc D, Weber S. High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. J Rheumatol. 2004 [acceso 05/03/2022];31(10):1941-5. Disponible en: https://pubmed.ncbi.nlm.nih.gov19.

  20. Lobos Bejarano JM, Horrillo García C, González-González AI, Castellanos Rodríguez Á, Díaz Sánchez S, Castellanos Maroto J. Validez y utilidad del péptido ventricular natriurético tipo B (BNP) en la detección de disfunción ventricular izquierda en pacientes de alto riesgo en atención primaria. Aten. Prim. 2012 [acceso 05/03/2022];44(1):13-19. Disponible en: https://www.ncbi.nlm.nih.gov20.

  21. García de la Peña Lefebvre P. Esclerosis sistémica y síndromes esclerodermiformes, En: Manual Ser de enfermedades reumáticas. 6ta Edición. Sociedad Española de Reumatología; Madrid: Elsevier; 2014 [acceso 05/03/2022]. 363-71. Disponible en: https://www.academia.edu21.

  22. Jiménez-Navarro M, Delgado Jiménez J, Rivera Otero M, Segovia Cubero J, Almenar Bonet L, Anguita Sánchez M, et al. Utilidad de los péptidos natriuréticos en la insuficiencia cardíaca. Med Clin (Barc). 2008;130(15):591-6. DOI: http://doi.org/10.1157/1311998222.

  23. Olivero Soldevila S. Esclerosis sistémica: supervivencia y factores pronósticos. Universidad Autónoma de Barcelona. 2013. p.2-102.

  24. Silveira-Torre LH. Afección cardíaca en la esclerosis sistémica. Reumatología Clinica. 2006;2(Supl 3):S531-6. DOI: https://doi.org/10.1016/S1699-258X(06)73105-924.




2020     |     www.medigraphic.com